



RELAY THERAPEUTICS STRENGTHENS R&D LEADERSHIP TEAM WITH KEY ADDITIONS IN CHEMISTRY AND PHARMACEUTICAL DEVELOPMENT

Cambridge, Mass.,” December 4, 2018 - [Relay Therapeutics](#), a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the appointments of Mary Mader, Ph.D., as vice president of chemistry, and Mahesh Padval, Ph.D., as senior vice president of pharmaceutical drug development.

“We welcome Mary and Mahesh to Relay Therapeutics, both key additions to our senior R&D leadership team,” said Don Bergstrom, M.D., Ph.D., head of research and development at Relay Therapeutics. “Their experience as seasoned biopharma executives will bolster our capabilities as we apply our protein motion platform to an expanding array of therapeutic targets, as well as support our transition into a development-stage biotechnology company.”

Dr. Mader brings a long track record of drug discovery experience to Relay Therapeutics. She joins the company from Eli Lilly and Company, where she contributed to the development of multiple clinical candidates and held roles of increasing responsibility, most recently as a research fellow and group leader. Prior to Eli Lilly, Dr. Mader was a visiting research scientist at the Bayer Research Center and an associate professor at Grinnell College. Dr. Mader received her Ph.D. from the University of Notre Dame and her Bachelor of Science from the Ohio State University.

Prior to joining Relay Therapeutics, Dr. Padval was vice president of pharmaceutical sciences and product development at Verastem, Inc. There, he was responsible for preclinical development, CMC, and clinical pharmacology activities in support of company’s development programs through non-clinical, clinical development and regulatory filings, including the recent approval and commercial launch of COPIKTRA™. Prior to Verastem, Dr. Padval held roles of increasing responsibility at Zalicus, Inc., culminating in his role as vice president of preclinical development and formulations. Dr. Padval also held roles at Charles River Discovery and Development Services and Genzyme Transgenics Corporation. Dr. Padval received his Ph.D. and M.S. in industrial pharmacy from Massachusetts College of Pharmacy, and a Bachelor of Pharmacy from the University of Bombay, India.

About Relay Therapeutics

Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach and by focusing on disease-causing targets, Relay aims to develop breakthrough

medicines for patients in need. The company's initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 and has raised \$120 million in financing to date from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital, Section 32, Alexandria Venture Investments, and an affiliate of D. E. Shaw Research.

###

Media Contact:

Dan Budwick

1AB

(973) 271-6085

dan@labmedia.com